Christos Zoupas DIABETOLOGIST Director, Diabetes Department

• Scintigraphy study in polycystic kidney disease (Athens University Medical School – 1973). 

• European Association for the Study of Diabetes (EASD) Fellow Member of the Board 1984-87
• Diabetic Pregnancy Study Group (DPSG) of EASD Fellow member Chairman of the board 2004 – 2005
• International Society of Diabetic Pregnancy Study Groups (ISDPSG) Fellow member
• American Diabetes Association (ADA) Fellow member Organizing Committee – 5th International Workshop of the GDM of ADA, Chicago 2005
• International Diabetic Federation (IDF) Fellow member
• Mediterranean Group for the Study of Diabetes (MGSD) Fellow member
• Hellenic Diabetes Association (HAD) Fellow member
• Hellenic Endocrinological Society Fellow member
• Hellenic Association for Obesity, Metabolism and Endocrinological Disorders (HASHOMED) Chairman of the Board

Editorial Boards:
AD-HOC REVIEWER for peer-reviewed international journals

• Diabetes Care
• Diabetologia

• 1974 – 1975: Director, Department of Internal Medicine Kalamata General Hospital. Greece
• 1975 – 1976: Staff physician, Clinical Endocrinology and Metabolism Alexandra Hospital, Athens University, Greece
• 1978 – 1982: Clinical Instructor, Diabetes Center Department of Clinical Therapeutics Alexandra Hospital, Athens University, Greece
• 1982 – 1986: Director, Diabetes Center Department of Clinical Therapeutic Alexandra Hospital, Athens, Greece
• 1986 – Present Director, Diabetic Center Hygeia General Hospital, Athens, Greece

Education Experience:

• Participation in more than 200 international meetings 

Clinical Interest

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus
• Insulin Pump therapy in Diabetes
• Gestational Diabetes, Diabetic Foot
• Diabetic Neuropathy and Angiopathy

Research Interest

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus
• Insulin Pump therapy in Diabetes
• Gestational Diabetes, Diabetic Foot
• Diabetic Neuropathy and Angiopathy

• Received numerous awards and honours from governmental, medical, religious and athletic leaders of Greece.

• Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry. Cohen O, Korner A, Chlup R, Zoupas CS, Ragozin AK, Wudi K, Bartaskova D, Pappas A, Niederland T, Taybani Z, Barak L, Vazeou A; Central and Eastern Europe, Greece, and Israel Continuous Glucose Sensing Collaborative Study Group. J Diabetes Sci Technol. 2009 Jul 1;3(4):804-11.
• Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ, Sacks DA, Zoupas C. Diabetes Care. 2007 Jul;30 Suppl 2:S251-60. doi: 10.2337/dc07-s225. Diabetes Care. 2007 Dec;30(12):3154.
• The importance of insulin administration in gestational diabetics. Zoupas C, Mastrantonakis E, Diakakis I, Fakas G, Michalas S, Kalpogiannis N, Aravantinos D, Kaskarelis D. Acta Endocrinol Suppl (Copenh). 1984;265:26-8.
• Effect of induced hyperglycemia on contrast sensitivity function in insulin-dependent diabetic patients. Mangouritsas G, Katoulis E, Kepaptsoglou O, Zoupas C. Ophthalmologe. 1995 Apr;92(2):142-7.
• Evaluation of continuous use of Real Time Glucose Monitoring (PRT), alone and combined with Insulin Pump Therapy, as a mean to normalize Glycaemic Control in IDDM. Zoupas CS, Kepaptsoglou O, Taraoune I, Giannakopoulos F, Garoutsou P, Barreto C, Vasilopoulos H, Kefaloyannis N, Kyrlaki E, Pappas A. Diabetes. June 2008;57(S1).
• One year continuous use of Real Time Glucose Monitoring combined with Insulin Pump, as a mean to normalize Glucose Variability and HbA1c in IDDM. Zoupas CS, Kepaptsoglou O, Kefaloyannis N, Taraoune I, Giannakopoulos F, Sfakianaki M, Garoutsou P, Vasilopoulos H, Kyrlaki E, Pappas A. Diabetologia. Sept. 2008;51(S1).
• Intensification of Therapy and Better Glucose Control after the Continuous Use of-Real Time Glucose Monitoring combined with Insulin Pump (PRT system) inType 1 Diabetes Melitus. Pappas AC , Kepaptzoglou O, Kyrlaki E, Taraoune I, Sfakianaki M, Garoutsou P, Vasilopoulos H, Kefaloyannis N, Zoupas CS. Diabetes. June 2009;58(S1). 
• Pump users and insulin infusion sets during financial crisis: A matter of consideration? P. Thomakos, O. Kepaptsoglou, I. Taraoune, C. Barreto, C. Zoupas. Diabetes Technology & Therapeutics. February 2015, 17(S1): A-69.
• Which factors may affect the quality of life in patients with Type 1 Diabetes Mellitus using Continuous Subcutaneous Insulin Infusion pumps? P. Thomakos, A. Mitrakou, O. Kepaptsoglou, I. Taraoune, C. Barreto, A. Pappas, C. Zoupas. Diabetes Technology & Therapeutics. February 2016, 18(S1): A-113-114.